- Home
- BNTX vs EQR Comparison
BNTX vs EQR Comparison
Compare BNTX & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTX
- EQR
- Stock Information
- Founded
- BNTX 2008
- EQR 1993
- Country
- BNTX Germany
- EQR United States
- Employees
- BNTX N/A
- EQR N/A
- Industry
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- EQR Real Estate Investment Trusts
- Sector
- BNTX Health Care
- EQR Real Estate
- Exchange
- BNTX Nasdaq
- EQR Nasdaq
- Market Cap
- BNTX 25.0B
- EQR 26.7B
- IPO Year
- BNTX 2019
- EQR 1993
- Fundamental
- Price
- BNTX $106.53
- EQR $68.99
- Analyst Decision
- BNTX Strong Buy
- EQR Buy
- Analyst Count
- BNTX 18
- EQR 15
- Target Price
- BNTX $141.55
- EQR $79.00
- AVG Volume (30 Days)
- BNTX 1.2M
- EQR 1.7M
- Earning Date
- BNTX 08-04-2025
- EQR 07-28-2025
- Dividend Yield
- BNTX N/A
- EQR 4.01%
- EPS Growth
- BNTX N/A
- EQR 8.50
- EPS
- BNTX N/A
- EQR 2.62
- Revenue
- BNTX $2,968,331,171.00
- EQR $3,010,100,000.00
- Revenue This Year
- BNTX N/A
- EQR $5.26
- Revenue Next Year
- BNTX $10.68
- EQR $4.34
- P/E Ratio
- BNTX N/A
- EQR $26.40
- Revenue Growth
- BNTX 0.61
- EQR 3.81
- 52 Week Low
- BNTX $76.53
- EQR $59.41
- 52 Week High
- BNTX $131.49
- EQR $78.84
- Technical
- Relative Strength Index (RSI)
- BNTX 54.09
- EQR 48.12
- Support Level
- BNTX $102.24
- EQR $68.36
- Resistance Level
- BNTX $108.56
- EQR $69.42
- Average True Range (ATR)
- BNTX 4.00
- EQR 1.21
- MACD
- BNTX -0.35
- EQR -0.04
- Stochastic Oscillator
- BNTX 20.76
- EQR 45.05
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.